BACKGROUND: The OCTANE trial reports superior outcomes of lopinavir/ritonavir vs. nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine. METHODS: We used a computer model, with OCTANE and local data, to simulate HIV-infected, single-dose nevirapine-exposed women in South Africa. Outcomes of three alternative ART sequences were projected: no ART (for comparison), first-line nevirapine, and first-line lopinavir/ritonavir. OCTANE data included mean age (31 years) and CD4 cell count (135/μl); median time since single-dose nevirapine (17 months); and 24-week viral suppression efficacy for first-line ART (nevirapine: 85%, lopinavir/ritonavir: 97%). Outcomes included life expectancy, per-person costs (2008 US$), and incremental cost-effectiveness ratios. RESULTS: With no ART, projected life expectancy was 1.6 years and per-person cost was $2980. First-line nevirapine increased life expectancy (15.2 years) and cost ($13 990; cost-effectiveness ratio: $810/year of life saved versus no ART). First-line lopinavir/ritonavir further increased life expectancy to 16.3 years and cost to $15 630 (cost-effectiveness ratio: $1520/year of life saved versus first-line nevirapine). First-line lopinavir/ritonavir cost-effectiveness was sensitive to prevalence of nevirapine-resistant virus at ART initiation, time from single-dose nevirapine exposure to ART initiation (6-12, 12-24, or >24 months), second-line ART efficacies, and outcomes after 24 weeks on ART. CONCLUSIONS: First-line lopinavir/ritonavir-based ART is very cost-effective in single-dose nevirapine-exposed, South African women similar to OCTANE participants. Lopinavir/ritonavir should be initiated in women with known nevirapine resistance or single-dose nevirapine exposure less than 12 months prior, or in whom such information is unknown.
BACKGROUND: The OCTANE trial reports superior outcomes of lopinavir/ritonavir vs. nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine. METHODS: We used a computer model, with OCTANE and local data, to simulate HIV-infected, single-dose nevirapine-exposed women in South Africa. Outcomes of three alternative ART sequences were projected: no ART (for comparison), first-line nevirapine, and first-line lopinavir/ritonavir. OCTANE data included mean age (31 years) and CD4 cell count (135/μl); median time since single-dose nevirapine (17 months); and 24-week viral suppression efficacy for first-line ART (nevirapine: 85%, lopinavir/ritonavir: 97%). Outcomes included life expectancy, per-person costs (2008 US$), and incremental cost-effectiveness ratios. RESULTS: With no ART, projected life expectancy was 1.6 years and per-person cost was $2980. First-line nevirapine increased life expectancy (15.2 years) and cost ($13 990; cost-effectiveness ratio: $810/year of life saved versus no ART). First-line lopinavir/ritonavir further increased life expectancy to 16.3 years and cost to $15 630 (cost-effectiveness ratio: $1520/year of life saved versus first-line nevirapine). First-line lopinavir/ritonavir cost-effectiveness was sensitive to prevalence of nevirapine-resistant virus at ART initiation, time from single-dose nevirapine exposure to ART initiation (6-12, 12-24, or >24 months), second-line ART efficacies, and outcomes after 24 weeks on ART. CONCLUSIONS: First-line lopinavir/ritonavir-based ART is very cost-effective in single-dose nevirapine-exposed, South African women similar to OCTANEparticipants. Lopinavir/ritonavir should be initiated in women with known nevirapine resistance or single-dose nevirapine exposure less than 12 months prior, or in whom such information is unknown.
Authors: Rochelle P Walensky; Lindsey L Wolf; Robin Wood; Mariam O Fofana; Kenneth A Freedberg; Neil A Martinson; A David Paltiel; Xavier Anglaret; Milton C Weinstein; Elena Losina Journal: Ann Intern Med Date: 2009-07-20 Impact factor: 25.391
Authors: Jody Lawrence; Douglas L Mayers; Katherine Huppler Hullsiek; Gary Collins; Donald I Abrams; Ronald B Reisler; Lawrence R Crane; Barry S Schmetter; Thomas J Dionne; Jennifer M Saldanha; Michael C Jones; John D Baxter Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: David Coetzee; Katherine Hildebrand; Andrew Boulle; Gary Maartens; Francoise Louis; Veliswa Labatala; Hermann Reuter; Nonthutuzelo Ntwana; Eric Goemaere Journal: AIDS Date: 2004-04-09 Impact factor: 4.177
Authors: James A McIntyre; Mark Hopley; Daya Moodley; Marie Eklund; Glenda E Gray; David B Hall; Patrick Robinson; Douglas Mayers; Neil A Martinson Journal: PLoS Med Date: 2009-10-27 Impact factor: 11.069
Authors: Jeffrey S A Stringer; Michelle S McConnell; James Kiarie; Omotayo Bolu; Thanomsak Anekthananon; Tavatchai Jariyasethpong; Dara Potter; Winnie Mutsotso; Craig B Borkowf; Dorothy Mbori-Ngacha; Peter Muiruri; John Odero Ong'ech; Isaac Zulu; Lungowe Njobvu; Bongkoch Jetsawang; Sonal Pathak; Marc Bulterys; Nathan Shaffer; Paul J Weidle Journal: PLoS Med Date: 2010-02-16 Impact factor: 11.069
Authors: Sarah B Lorenzana; Michael D Hughes; Beatriz Grinsztejn; Ann C Collier; Paula Mendes Luz; Kenneth A Freedberg; Robin Wood; Julie H Levison; Peter N Mugyenyi; Robert Salata; Carole L Wallis; Milton C Weinstein; Robert T Schooley; Rochelle P Walensky Journal: AIDS Date: 2012-06-01 Impact factor: 4.177
Authors: Andrea L Ciaranello; Freddy Perez; Matthews Maruva; Jennifer Chu; Barbara Engelsmann; Jo Keatinge; Rochelle P Walensky; Angela Mushavi; Rumbidzai Mugwagwa; Francois Dabis; Kenneth A Freedberg Journal: PLoS One Date: 2011-06-02 Impact factor: 3.240
Authors: Andrea L Ciaranello; Freddy Perez; Jo Keatinge; Ji-Eun Park; Barbara Engelsmann; Matthews Maruva; Rochelle P Walensky; Francois Dabis; Jennifer Chu; Asinath Rusibamayila; Angela Mushavi; Kenneth A Freedberg Journal: PLoS Med Date: 2012-01-10 Impact factor: 11.069
Authors: Shahin Lockman; Michael Hughes; Fred Sawe; Yu Zheng; James McIntyre; Tsungai Chipato; Aida Asmelash; Mohammed Rassool; Sylvester Kimaiyo; Douglas Shaffer; Mina Hosseinipour; Lerato Mohapi; Francis Ssali; Margret Chibowa; Farida Amod; Elias Halvas; Evelyn Hogg; Beverly Alston-Smith; Laura Smith; Robert Schooley; John Mellors; Judith Currier Journal: PLoS Med Date: 2012-06-12 Impact factor: 11.069
Authors: Gesine Meyer-Rath; Jan Pienaar; Brian Brink; Andrew van Zyl; Debbie Muirhead; Alison Grant; Gavin Churchyard; Charlotte Watts; Peter Vickerman Journal: PLoS Med Date: 2015-09-01 Impact factor: 11.069
Authors: Andrea L Ciaranello; Bethany L Morris; Rochelle P Walensky; Milton C Weinstein; Samuel Ayaya; Kathleen Doherty; Valeriane Leroy; Taige Hou; Sophie Desmonde; Zhigang Lu; Farzad Noubary; Kunjal Patel; Lynn Ramirez-Avila; Elena Losina; George R Seage; Kenneth A Freedberg Journal: PLoS One Date: 2013-12-13 Impact factor: 3.240